Skip to content

Category: Science Medical

UNSW SMaRT Centre study finds purification uses for textiles and other wastes

By API User

UNSW SMaRT Centre researchers have had published a study revealing multiple research findings around valuable new uses for textile and other wastes as sources of activated carbon for essential “purification” applications.  In its latest published report by Elsevier into creating “activated carbon” from waste textiles, the UNSW Sustainable Materials Research and Technology (SMaRT) Centre says the findings … Continued

New carbon-conversion technology could turn emissions into jet fuel

By API User

RMIT researchers have developed a carbon‑conversion technology that may one day help turn industrial emissions into jet fuel, by simplifying how carbon dioxide is recycled. The system combines carbon removal and conversion into a single process, reducing the energy use and complexity that limits many existing approaches. The technology is designed with real‑world industrial settings … Continued

Concept Medical Announces First Patient Enrollment in STARS DAPT Randomized Clinical Trial Evaluating Abluminus NP Polymer-Free DES

By API User

TAMPA, Fla.–BUSINESS WIRE– Concept Medical Inc., a global pioneer in innovative drug delivery technology, is proud to announce the successful enrollment of the first patients in the STARS DAPT (ST-Segment Elevation Myocardial InfArction treated with a Polymer-Free Sirolimus-based NanocarrieR Eluting Stent and a P2Y12 inhibitor-based Single Antiplatelet Strategy after a Short Dual Antiplatelet Therapy versus … Continued

SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing

By API User

BEIJING–BUSINESS WIRE– Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request to continue its listing on the Nasdaq Stock Market, subject to stated conditions focused on timely completion of its financial audit and … Continued

IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio

By API User

At IMCAS 2026, Galderma will present findings supporting Sculptra’s® regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7 Multiple studies will reinforce the safety and efficacy of Galderma’s hyaluronic acid (HA) … Continued

Get active for your brain health and beat dementia in Canberra!

By API User

The 2026 Canberra Memory Walk & Jog is just weeks away, with the event taking place on Sunday 22 February at Stage 88, Commonwealth Park.   As Dementia Australia’s largest annual fundraising initiative, Memory Walk & Jog brings communities together to get active, get connected and support Australians living with dementia, their families and carers. … Continued

Patients co-design world-first clinical trial to determine if invasive heart surgery monitoring helps or harms patients

By API User

Australians undergoing open-heart surgery could soon benefit from safer, simpler care and get home earlier thanks to the results of a world-first clinical trial led by Monash University’s Victorian Heart Institute. The PUMA trial has been co-designed with patients and their families to determine if invasive devices used to monitor cardiac function during and after … Continued

Drinking less could prevent thousands of cancer deaths, study shows

By API User

Reducing annual alcohol consumption in Australia by one litre a person could significantly lower deaths from several major cancers, particularly among older Australians, a new study led by La Trobe University has found. Using more than 70 years of national mortality, alcohol and tobacco consumption, and health-expenditure data, researchers examined how long-term population level alcohol … Continued

Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership

By API User

ZUG, Switzerland–BUSINESS WIRE– Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirming the termination of a 2014 neuromodulator research & development partnership with Ipsen. The partnership was limited to the rights and obligations relating to the companies’ early-stage neuromodulator pipeline for aesthetic indications. … Continued